Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development

Author(s): Zhao-Hui Wu and Yuling Shi

Volume 19, Issue 18, 2013

Page: [3263 - 3275] Pages: 13

DOI: 10.2174/1381612811319180010

Price: $65

Abstract

During the last two decades, the studies on ubiquitination in regulating transcription factor NF-κB activation have elucidated the expanding role of ubiquitination in modulating cellular events by non-proteolytic mechanisms, as well as by proteasomal degradation. The significance of ubiquitination has also been recognized in regulating gene transcription, epigenetic modifications, kinase activation, DNA repair and subcellular translocation. This progress has been translated into novel strategies for developing anti-cancer therapeutics, exemplified by the success of the first FDA-approved proteasome inhibitor drug Bortezomib. Here we discuss the current understanding of the ubiquitin-proteasome system and how it is involved in regulating NF-κB signaling pathways in response to a variety of stimuli. We also focus on the recent progress of anti-cancer drug development targeting various steps of ubiquitination process, and the potential of these drugs in cancer treatment as related to their impact on NF-κB activation.

Keywords: Ubiquitin, NF-κB, cancer, therapeutics.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy